ClinicalTrials.Veeva

Menu

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

L

Laniado Hospital

Status and phase

Terminated
Phase 4

Conditions

Diabetes Mellitus Type 2

Treatments

Drug: Basal insulins
Drug: Lixisenatide

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog.

Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.

Enrollment

2 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of non-fasting glycemic control

Exclusion criteria

  • Pregnant or lactating woman
  • Renal failure (eGFR<30)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

2 participants in 1 patient group

Lixisenatide
Experimental group
Description:
S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
Treatment:
Drug: Lixisenatide
Drug: Basal insulins

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems